2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician’s choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI:10.1136/ijgc-2022-esgo.762

V. Salutari, L. Musacchio, S. Pignata, E. Braicu, D. Cibula, N. Colombo, J. Frenel, S. Giolitto, Floriana Camarda, M. Perri, E. Giudice, G. Scambia, D. Lorusso

{"title":"2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician’s choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)","authors":"V. Salutari, L. Musacchio, S. Pignata, E. Braicu, D. Cibula, N. Colombo, J. Frenel, S. Giolitto, Floriana Camarda, M. Perri, E. Giudice, G. Scambia, D. Lorusso","doi":"10.1136/ijgc-2022-esgo.762","DOIUrl":null,"url":null,"abstract":"higher FIGO stage(p<0.001), high-grade(p=0.003), serous tumours(p=0.006) and residual tumour as compared to local PC(p<0.001). Wet PC significantly correlated with diffuse localization(p <0.001) and residual tumour as compared to dry PC(p<0.001). Coarse PC was significantly associated with residual tumour as compared to fine PC(p=0.044). Diffuse peritoneal localization(p<0.001), wet PC(p<0.001), and lymph-node involvement(p<0.001) were associated with lower OS and PFS-rates. Conclusion Diffuse PC was a significant predictor of recurrence. Lower OS and PFS were associated with diffuse PC, wet PC, and additional lymph node involvement. Further pro-spective trials are warranted with the inclusion of translational research aspects to better understand the different peritoneal carcinomatosis pattern.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"43 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ovarian cancer and other gynecologic malignancies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-esgo.762","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

higher FIGO stage(p<0.001), high-grade(p=0.003), serous tumours(p=0.006) and residual tumour as compared to local PC(p<0.001). Wet PC significantly correlated with diffuse localization(p <0.001) and residual tumour as compared to dry PC(p<0.001). Coarse PC was significantly associated with residual tumour as compared to fine PC(p=0.044). Diffuse peritoneal localization(p<0.001), wet PC(p<0.001), and lymph-node involvement(p<0.001) were associated with lower OS and PFS-rates. Conclusion Diffuse PC was a significant predictor of recurrence. Lower OS and PFS were associated with diffuse PC, wet PC, and additional lymph node involvement. Further pro-spective trials are warranted with the inclusion of translational research aspects to better understand the different peritoneal carcinomatosis pattern.

查看原文本刊更多论文

尼拉帕尼- tsr -042(多司利单抗)与医生在不适合铂类药物再治疗的复发性卵巢癌、输卵管癌或原发性腹膜癌患者中的选择的随机III期试验:NItCHE试验(MITO 33)

FIGO分期较高(p<0.001)、高级别(p=0.003)、浆液性肿瘤(p=0.006)和残余肿瘤(p<0.001)。与干性PC相比，湿性PC与弥漫性定位(p<0.001)和残留肿瘤显著相关(p<0.001)。与细粒PC相比，粗粒PC与肿瘤残留显著相关(p=0.044)。弥漫性腹膜定位(p<0.001)、湿性PC(p<0.001)和淋巴结受累(p<0.001)与较低的OS和pfs率相关。结论弥漫性PC是复发的重要预测因子。较低的OS和PFS与弥漫性PC、湿性PC和额外的淋巴结受累有关。为了更好地了解不同的腹膜癌模式，进一步的前瞻性试验需要纳入转化研究方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical ovarian cancer and other gynecologic malignancies

自引率

0.00%

发文量